|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
In addition to CBZ, HLA-B*5801 was also found to associate with allopurinol-induced TEN/SJS.
|
20536296 |
2010 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
HLA-B*1502 genotyping with sequence-specific primer polymerase chain reaction (PCR-SSP) and PCR-sequencing based typing (PCR-SBT) was performed on 17 CBZ-induced SJS/TEN patients, 21 CBZ-tolerant controls, and 185 healthy controls recruited during 2008-2010.
|
21424386 |
2011 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
HLA-B*5801 is highly associated with the allopurinol-induced toxic epidermal necrolysis and Stevens-Johnson syndrome.
|
29642234 |
2018 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
CTD_human |
Medical genetics: a marker for Stevens-Johnson syndrome.
|
15057820 |
2004 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The sensitivity and specificity of the HLA-B*5801 allele for prediction of allopurinol-induced SJS/TEN were 100 and 87%, respectively.
|
19696695 |
2009 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
In addition, our HLA genotyping results are consistent with previous studies reporting a strong association between HLA-B*58:01 and allopurinol-induced SJS/TEN among Koreans.
|
26655481 |
2016 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our results suggest that HLA-B*15:02 is necessary but is not sufficient to produce SJS/TEN following CBZ treatment among Han individuals from northeastern China.
|
24399721 |
2013 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The HLA-B*15:02 polymorphism was also strongly associated with the CBZ-SJS subgroup (OR: 152.089, 95% CI: 34.737-665.901) and significantly associated with the CBZ-SJS/TEN subgroup (OR: 13.993, 95% CI: 7.291-26.856).
|
29685430 |
2018 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
HLA-B*15:02 association with carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in an Indian population: a pooled-data analysis and meta-analysis.
|
25266342 |
2014 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Due to the significant risk of developing Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), the use of carbamazepine is not recommended in patients carrying the human leukocyte antigen B (HLA-B) *15:02 allele.
|
28440597 |
2018 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
HLA gene frequencies varied in Korea.Screening of HLA-B*58:01 before the use of allopurinol might be needed to anticipate probability of SJS/TEN.
|
26632391 |
2016 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Previous studies have reported that patients with phenytoin-induced Stevens-Johnson syndrome and toxic epidermal necrolysis (PHT-induced SJS/TEN) were positive for HLA-B*1502.
|
21216202 |
2011 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This has led to the recommendation that patients of Asian ancestry be tested for the HLA-B*1502 allele, in order to identify those at high risk of developing Stevens-Johnson syndrome and toxic epidermal necrolysis after administration of carbamazepine and, possibly, phenytoin and other antiepileptic drugs.
|
19262378 |
2009 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Studies have reported an association of HLA-B*1502 and HLA-B*5801 in patients with the Stevens-Johnson syndrome or toxic epidermal necrolysis provoked by carbamazepine, as well as of HLA-B*5701 with abacavir hypersensitivity.
|
18991696 |
2008 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Previously, we have reported the association of HLA-A*02:06 and HLA-B*44:03 with cold medicine (CM)-related SJS/TEN with severe ocular complications (SOCs) in the Japanese population.
|
31700100 |
2019 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our data suggest that HLA-B*1502 could contribute to the pathogenesis of CBZ-SJS/TEN, and that genetic susceptibility to CBZ-induced cADRs is phenotype-specific.
|
16538176 |
2006 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
HLA-B*15:02 for carbamazepine-induced SJS/TEN and HLA-B*58:01 for allopurinol-induced SCAR), involvement of specific TCR, induction of T-cell-mediated responses (e.g. granulysin, Fas ligand, perforin/granzyme B and T-helper 1/2-associated cytokines) and cell death mechanism (e.g. miR-18a-5p-induced apoptosis; annexin A1 and formyl peptide receptor 1-induced necroptosis in keratinocytes).
|
27154258 |
2016 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Available data also suggest that HLA-B*1502 is a risk allele for SJS/TEN caused by other aromatic AEDs with a similar structure to CBZ.
|
20001755 |
2010 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Performing HLA-B*1502 genotyping and avoiding carbamazepine in at-risk individuals has been proven to decrease incidences of drug-induced TEN.
|
26319500 |
2015 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
CTD_human |
Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations.
|
18855540 |
2008 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
We found that HLA-B*44:03 was significantly associated with CM-SJS/TEN with SOC in the Indian and Brazilian but not the Korean population, and that HLA-A*02:06 might be weakly associated in the Korean- but not the Indian and Brazilian population.
|
25099678 |
2014 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
We first identified that HLA-B*1502 is strongly associated with carbamazepine (CBZ)-induced SJS/TEN and HLA-B*5801 with allopurinol-SJS/TEN in Han Chinese.
|
20962567 |
2010 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The presence of HLA-B*15:02 and CYP2C9 *2 or *3 in the same patient increases the risk of Stevens-Johnson syndrome and toxic epidermal necrolysis; hence, PHT should not be prescribed in these patients.
|
29636628 |
2018 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
HLA-B genotyping was performed on 150 patients included in a European study (RegiSCAR) of SJS and TEN.
|
18192896 |
2008 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We speculated that Korean individuals expressing the HLA-B*4403 allele may be highly susceptible to lamotrigine-induced SJS/TEN.
|
25327504 |
2015 |